Russ Conroy

Articles

Prospective, Real-World Study Highlights Feasibility of Outpatient Robotic Partial Nephrectomy in Renal Tumors

April 29th 2025

A high proportion of patients with renal tumors were discharged on the same day after receiving robotic partial nephrectomy.

Retrospective Study Shows Variability of Interventions for Blinatumomab-Related Neurotoxicity in Hematologic Malignancies

April 11th 2025

A retrospective study found that interventions for patients experiencing grade 2 vs 3 blinatumomab-associated ICANS were not consistently implemented.

Rina-S Generates Durable Responses in Advanced Platinum-Resistant Ovarian Cancer

March 17th 2025

The median DOR with Rina-S was not reached and the treatment was well tolerated in patients with FRα-unselected platinum-resistant ovarian cancer.

Zimberelimab Plus Lenvatinib Shows Activity in ICI-Pretreated Advanced Cervical Cancer

March 15th 2025

The combination of zimberelimab and lenvatinib had antitumor activity and a manageable safety profile in pretreated advanced cervical cancer.

Afuresertib Plus Paclitaxel Does Not Elicit Substantial Clinical Benefit in Platinum-Resistant Ovarian Cancer

March 15th 2025

Afuresertib combined with paclitaxel did not elicit PFS or OS benefits vs paclitaxel alone in patients with unselected platinum-resistant ovarian cancer.

Olaparib After Durvalumab/Chemo Boosts PFS in Subgroups of pMMR Endometrial Cancer

March 15th 2025

Olaparib maintenance following durvalumab plus chemotherapy improved PFS in different subgroups of pMMR endometrial cancer.

Pembrolizumab Plus Concurrent Chemoradiotherapy Improves OS, PFS2 in Advanced Cervical Cancer

March 15th 2025

The addition of pembrolizumab to chemoradiotherapy prolonged survival and time to second progression in patients with locally advanced cervical cancer.

Neoadjuvant Chemo and Concurrent Chemoradiation Is a Safe, Effective Bladder-Sparing Approach in Nonmetastatic MIBC

February 18th 2025

Neoadjuvant chemotherapy and concurrent chemoradiation could represent a safe, effective bladder-sparing approach in MIBC.

Perioperative Lenvatinib Plus Pembrolizumab Is Safe and Effective in Advanced ccRCC

February 15th 2025

Neoadjuvant lenvatinib plus pembrolizumab followed by adjuvant pembrolizumab was safe and effective in patients with locally advanced, nonmetastatic ccRCC.

Lenvatinib Plus Belzutifan Demonstrates Antitumor Activity in Advanced ccRCC

February 15th 2025

Greater responses were observed in a cohort of patients with renal cell carcinoma receiving lenvatinib plus belzutifan vs pembrolizumab plus lenvatinib.

Dato-DXd Prolongs Responses in Pretreated Advanced/Metastatic Urothelial Cancer

February 15th 2025

Dato-DXd generated durable responses and produced no new safety signals in patients with heavily pretreated, locally advanced/metastatic urothelial cancer.

EBRT With or Without STAD Shows Improved 15-Year Survival in Prostate Cancer

February 13th 2025

Treatment of EBRT with or without STAD for 6 months demonstrated an improvement in prostate cancer-specific survival in intermediate-risk prostate cancer.

Retrospective Analysis Shows Frailty Leads to Worsened Outcomes After Surgery in Gynecologic Cancers

January 31st 2025

Postoperative outcomes may be worse among patients with gynecologic cancers who are elderly or frail.

BRAF V600E-Mutant Metastatic CRC Confers Poor Survival Outcomes Regardless of Synchronous vs Metachronous Status

January 30th 2025

Patients with BRAF V600E-mutant metastatic colorectal cancer experience poor clinical outcomes, according to real-world data.

OS With Chemotherapy Is Linked With Baseline Geriatric, QOL Factors in Metastatic Pancreatic Cancer

January 28th 2025

Overall survival data were linked with baseline geriatric assessment and QOL scores in patients with metastatic pancreatic ductal adenocarcinoma.

Nivolumab Plus Ipilimumab Prolongs PFS vs Nivolumab Alone in MSI-H/dMMR mCRC

January 25th 2025

Nivolumab plus ipilimumab led to early and sustained PFS benefits vs nivolumab alone across all lines of therapy in patients with dMMR/MSI-H mCRC.

Pamrevlumab Plus Chemo Fails to Improve Survival in Unresectable Locally Advanced Pancreatic Cancer

January 24th 2025

Pamrevlumab plus chemotherapy failed to demonstrate a survival benefit in patients with locally advanced, unresectable pancreatic cancer.

Surufatinib Plus TAS-102 Displays Activity, Safety in Later-Line Metastatic PDAC

January 24th 2025

Surufatinib with TAS-102 produced promising survival outcomes and manageable toxicity as later-line therapy for a small cohort of patients with PDAC.

Addition of Camrelizumab and Rivoceranib to TACE Boosts PFS in Unresectable HCC

January 24th 2025

TACE with camrelizumab and rivoceranib elicited a clinically meaningful PFS improvement among patients with unresectable HCC.

Trastuzumab/Pertuzumab/Chemo Does Not Confer Response Advantage in Gastric/GEJ Cancer

January 24th 2025

Trastuzumab/pertuzumab/chemotherapy was associated with higher rates of toxicity and no mpRR improvement vs chemotherapy alone in HER2+ gastric cancer.